Locating poor livestock keepers at the global level for research and development targeting

P.K. Thornton, R.L. Kruska, P.M. Kristjanson, R.S. Reid and T.P. Robinson are ILRI authorsMany research and development agencies are committed to halving the number of people living in extreme poverty by 2015. Knowledge of where the poor are, and what characterises them, is patchy at best. Here we describe a global livestock and poverty mapping study designed to assist in targeting research and development activities concerning livestock. Estimates of the numbers of poor livestock keepers by production system and region are presented. While these estimates suffer from various problems, improvements in global databases are critical to improve the targeting of interventions that can meet the challenges posed by poverty and to chart progress against international development indicators

An Observational Diagnostic for Ultraluminous X-Ray Sources

We consider observational tests for the nature of Ultraluminous X-ray sources (ULXs). These must distinguish between thermal-timescale mass transfer on to stellar-mass black holes leading to anisotropic X-ray emission, and accretion on to intermediate-mass black holes. We suggest that long-term transient behavior via the thermal-viscous disk instability could discriminate between these two possibilities for ULXs in regions of young stellar populations. Thermal-timescale mass transfer generally produces stable disks and persistent X-ray emission. In contrast, mass transfer from massive stars to black holes produces unstable disks and thus transient behavior, provided that the black hole mass exceeds some minimum value. This minimum mass depends primarily on the donor mass and evolutionary state. We show that it exceeds 50 solar masses for a large fraction (greater than 90%) of the mass-transfer lifetime for the most likely donors in young clusters. Thus if long-term monitoring reveals a large transient fraction among ULXs in a young stellar population, these systems would be good candidates for intermediate-mass black holes in a statistical sense; information about the donor star is needed to make this identification secure in any individual case. A transient ULX population would imply a much larger population of quiescent systems of the same type.Comment: 4 pages, 2 figure, ApJ Letters, in press (correct figure 2 included in this version

Using geospatial information to connect ecosystem services and human well-being in Kenya

The application of geospatial information in the analysis of ecosystem services would help decision makers to develop programs for poverty reduction in Kenya that would improve the targeting of social expenditures and ecosystem interventions so that they reach areas of greatest need

Pulsar Kicks and Spin Tilts in the Close Double Neutron Stars PSR J0737-3039, PSR B1534+12 and PSR B1913+16

In view of the recent measurement of the scintillation velocity for PSR J0737-3039, we examine the complete set of constraints imposed on the pulsar B natal kicks (magnitude and orientation) and predict the most favorable pulsar kick velocity and spin tilt for both isotropic and polar kicks. Our analysis takes into account both currently unknown parameters: the orientation of the orbital plane on the sky (Omega) and the radial component of the systemic velocity (V_r). Assuming that the system's peculiar velocity is entirely due to the second supernova explosion, we find that the system may have crossed the Galactic plane multiple times since the birth of the second neutron star and that the post-supernova peculiar velocity could have been as high as 1200km/s. We also confirm the absolute lower and upper limits on the physical parameters derived in our earlier study. For specific combinations of the two unknown parameters Omega and V_r, however, we find much tighter constraints on the pre-supernova binary configuration and natal kicks imparted to pulsar B, as well as on the age of system. Once Omega is measured in the coming year, it will be straightforward to use the results presented here to further constrain the natal kicks and the spin-tilt predictions. We complete our comprehensive study and derive similar constraints and spin-tilt predictions for PSR B1534+12, where the only free parameter is V_r. Lastly, for PSR B1913+16, we update the progenitor and kick constraints using the measured pulsar spin tilt and allowing for Roche-lobe overflow from the progenitor of the pulsar companion.Comment: Replaced Fig. 16 with corrected version. See ApJ 616, p. 414 for high-resolution figures and notes added in proo

Delayed Diagnosis in Cerebral Venous Thrombosis: Associated Factors and Clinical Outcomes.

Background Identifying factors associated with delayed diagnosis of cerebral venous thrombosis (CVT) can inform future strategies for early detection. Methods and Results We conducted a retrospective cohort study including all participants from ACTION-CVT (Anticoagulation in the Treatment of Cerebral Venous Thrombosis) study who had dates of neurologic symptom onset and CVT diagnosis available. Delayed diagnosis was defined as CVT diagnosis occurring in the fourth (final) quartile of days from symptom onset. The primary study outcome was modified Rankin Scale score of ≤1 at 90 days; secondary outcomes included partial/complete CVT recanalization on last available imaging and modified Rankin Scale score of ≤2. Logistic regression analyses were used to identify independent variables associated with delayed diagnosis and to assess the association of delayed diagnosis and outcomes. A total of 935 patients were included in our study. Median time from symptom onset to diagnosis was 4 days (interquartile range, 1-10 days). Delayed CVT diagnosis (time to diagnosis >10 days) occurred in 212 patients (23%). Isolated headache (adjusted odds ratio [aOR], 2.36 [95% CI, 1.50-3.73]; P10 days after symptom onset. Delayed CVT diagnosis was associated with the symptom of isolated headache and was not associated with adverse clinical outcomes

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

A large-scale, pooled analysis of safety data from five Phase III clinical trials (including open-label extensions of two of these studies) and two Phase III open-label clinical trials of efalizumab was conducted to explore whether arthropathy adverse events (AEs) were associated with efalizumab treatment in patients with moderate-to-severe chronic plaque psoriasis. Data from patients who received subcutaneous injections of efalizumab or placebo were stratified for analysis into phases according to the nature and duration of treatment. These included: the ‘first treatment’ phase (0–12-week data from patients who received either efalizumab, 1 mg/kg once weekly, or placebo in the five placebo-controlled studies); the ‘extended treatment’ phase (13–24-week data from seven trials for all efalizumab-treated patients); and the ‘long-term treatment’ phase (data from efalizumab-treated patients who received treatment for up to 36 months in two long-term trials). Descriptive statistics were performed and the incidence of arthropathy AEs per patient-year was calculated using 95% confidence intervals (CIs). During the first treatment phase, a similar proportion of patients had an arthropathy AE in the efalizumab group (3.3%; 58/1740 patients) compared with the placebo group (3.5%; 34/979 patients); the incidence of arthropathy AEs per patient-year was 0.15 in the efalizumab group (95% CI 0.11–0.19) and 0.16 in the placebo group (95% CI 0.11–0.22). Analysis of first treatment phase data from one study (n = 793) showed that the incidence of psoriatic arthropathy per patient-year was lower in efalizumab-treated patients (0.10; 95% CI 0.05–0.18) than in those given placebo (0.17; 95% CI 0.08–0.30). During the extended treatment phase, the incidence of arthropathy remained low (0.17; 95% CI 0.14–0.22). Data from two long-term studies showed that there was no increase in the incidence of arthropathy AEs over time in patients treated with efalizumab for up to 36 months. Patients who had an arthropathy AE during treatment with efalizumab appeared to be more likely to have a history of arthropathy prior to treatment. Efalizumab does not appear to increase the risk of arthropathy AEs compared with placebo

The dynamic clustering of insulin receptor underlies its signaling and is disrupted in insulin resistance

Insulin receptor (IR) signaling is central to normal metabolic control and is dysregulated in metabolic diseases such as type 2 diabetes. We report here that IR is incorporated into dynamic clusters at the plasma membrane, in the cytoplasm and in the nucleus of human hepatocytes and adipocytes. Insulin stimulation promotes further incorporation of IR into these dynamic clusters in insulin-sensitive cells but not in insulin-resistant cells, where both IR accumulation and dynamic behavior are reduced. Treatment of insulin-resistant cells with metformin, a first-line drug used to treat type 2 diabetes, can rescue IR accumulation and the dynamic behavior of these clusters. This rescue is associated with metformin’s role in reducing reactive oxygen species that interfere with normal dynamics. These results indicate that changes in the physico-mechanical features of IR clusters contribute to insulin resistance and have implications for improved therapeutic approaches

Stimulation of the Sphenopalatine Ganglion Induces Reperfusion and Blood-Brain Barrier Protection in the Photothrombotic Stroke Model

The treatment of stroke remains a challenge. Animal studies showing that electrical stimulation of the sphenopalatine ganglion (SPG) exerts beneficial effects in the treatment of stroke have led to the initiation of clinical studies. However, the detailed effects of SPG stimulation on the injured brain are not known.The effect of acute SPG stimulation was studied by direct vascular imaging, fluorescent angiography and laser Doppler flowmetry in the sensory motor cortex of the anaesthetized rat. Focal cerebral ischemia was induced by the rose bengal (RB) photothrombosis method. In chronic experiments, SPG stimulation, starting 15 min or 24 h after photothrombosis, was given for 3 h per day on four consecutive days. Structural damage was assessed using histological and immunohistochemical methods. Cortical functions were assessed by quantitative analysis of epidural electro-corticographic (ECoG) activity continuously recorded in behaving animals.Stimulation induced intensity- and duration-dependent vasodilation and increased cerebral blood flow in both healthy and photothrombotic brains. In SPG-stimulated rats both blood brain-barrier (BBB) opening, pathological brain activity and lesion volume were attenuated compared to untreated stroke animals, with no apparent difference in the glial response surrounding the necrotic lesion.SPG-stimulation in rats induces vasodilation of cortical arterioles, partial reperfusion of the ischemic lesion, and normalization of brain functions with reduced BBB dysfunction and stroke volume. These findings support the potential therapeutic effect of SPG stimulation in focal cerebral ischemia even when applied 24 h after stroke onset and thus may extend the therapeutic window of currently administered stroke medications

Simultaneous bilateral total ankle replacement using a 3-component prosthesis: Outcome in 26 patients followed for 2–10 years

Total ankle replacement is an established surgical procedure in patients with end-stage ankle osteoarthritis. We analyzed complications and medium-term results in patients with simultaneous bilateral total ankle replacement